Thank you to our speakers, sponsors, and delegates who joined us in Boston!

If you are interested in the 2024 event, returning December 10-12, please get in touch at info@hansonwade.com

Accelerating Screening & Discovery of Potent Covalent Inhibitors & Degraders with Improved Triaging, Selectivity & Safety for Targeting Hard-to-Drug Targets

Welcome to the Covalent Drug Discovery & Development Summit
Eliminating the Boundaries of Druggability with Novel Covalent Drugs

The field of targeted covalent therapeutics is seeing a surge of activity, with both new and established companies investing heavily in the space. The Covalent Drug Discovery & Development Summit will return this December to provide a dedicated forum to tackle associated challenges and advance covalent therapeutics; previously only afforded a small feature in larger ‘small molecule’ conferences.

As the very first meeting solely focused on covalent therapeutics, 2023's 18+ speaker faculty boasted leaders from large pharma, new biotech and academia. This was the summit to meet 80+ covalency experts gathering to solve target selectivity, hit screening, lead optimization, and covalent warhead design to carve out covalency’s niche for targeting the “undruggable” proteome.

Download the 2023 Full Event Guide for more information on:

  • 20+ Expert Speaker Faculty
  • Interactive workshops
  • Full access to the 3-day conference agenda
  • & more

The 2023 Speaker Faculty Included:

Companies Who Attended in 2023

34408 Companies attending

"I’m thrilled for the opportunity to come together with other covalent drug discovery leaders to help redefine the fight against the most undruggable diseases."
Neil Dhawan, CEO and Co-Founder, Totus Medicines

34478 - Banners (3)
34478 - Banners (6)
34478 - Banners (7)

Other Events in the Small Molecules & TPD World Series